COVID-19 Vaccination Rates in a Global HIV Cohort.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34794178.
- Also identified by DOI 10.1093/infdis/jiab575 and PMC identifier 8844595.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.
Medical subject headings
- COVID-19
- COVID-19 Vaccines
- HIV Infections
- Vaccination